Search results for "roe"

showing 10 items of 9822 documents

Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis.

2018

Abstract BACKGROUND AND AIM: Recent studies suggest an association between HCV infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. MATERIALS AND METHODS: One hundred eighty-two consecutive HCV patients with advanced fibrosis or compensated cirrhosis were evaluated by virological, anthropometric and metabolic measurements. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickne…

0301 basic medicineCarotid atherosclerosisCarotid Artery DiseasesMalemedicine.medical_specialtyCirrhosisSVRSustained Virologic ResponseHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsCarotid Intima-Media Thickness03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineGlucose homeostasisHumansIn patientProspective StudiesDAAHepatologybusiness.industryHepatitis C ChronicMiddle Agedmedicine.disease030104 developmental biologyTreatment OutcomeATHEROSCLEROSISHCVcardiovascular system030211 gastroenterology & hepatologyFemalebusinessDirect actingFollow-Up Studies
researchProduct

Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer.

2020

Cancer cells have unlimited replicative potential, insensitivity to growth-inhibitory signals, evasion of apoptosis, cellular stress, and sustained angiogenesis, invasiveness and metastatic potential. Cancer cells adequately adapt cell metabolism and integrate several intracellular and redox signaling to promote cell survival in an inflammatory and hypoxic microenvironment in order to maintain/expand tumor phenotype. The administration of tyrosine kinase inhibitor (TKI) constitutes the recommended therapeutic strategy in different malignancies at advanced stages. There are important interrelationships between cell stress, redox status, mitochondrial function, metabolism and cellular signali…

0301 basic medicineCell deathCell signalingClinical BiochemistryPGC-1αApoptosisReview ArticleBiochemistryReceptor tyrosine kinase03 medical and health sciencesPhosphatidylinositol 3-Kinases0302 clinical medicineNeoplasmsAutophagyTumor MicroenvironmentHumansProtein kinase AProtein kinase Blcsh:QH301-705.5Protein Kinase InhibitorsPI3K/AKT/mTOR pathwaylcsh:R5-920biologyOrganic ChemistryMitochondria030104 developmental biologylcsh:Biology (General)Redox statusCancer cellbiology.proteinCancer researchEndoplasmic reticulum stressmTORSignal transductionlcsh:Medicine (General)Tyrosine kinaseProto-Oncogene Proteins c-akt030217 neurology & neurosurgeryRedox biology
researchProduct

Conversion of Nonproliferating Astrocytes into Neurogenic Neural Stem Cells: Control by FGF2 and Interferon-gamma

2016

Abstract Conversion of astrocytes to neurons, via de-differentiation to neural stem cells (NSC), may be a new approach to treat neurodegenerative diseases and brain injuries. The signaling factors affecting such a cell conversion are poorly understood, and they are hard to identify in complex disease models or conventional cell cultures. To address this question, we developed a serum-free, strictly controlled culture system of pure and homogeneous “astrocytes generated from murine embryonic stem cells (ESC).” These stem cell derived astrocytes (mAGES), as well as standard primary astrocytes resumed proliferation upon addition of FGF. The signaling of FGF receptor tyrosine kinase converted G…

0301 basic medicineCell signalingNeurogenesisBiologyInterferon-gammaMice03 medical and health sciences0302 clinical medicineNeural Stem CellsNeurosphereddc:570medicineAnimalsCell ProliferationEpidermal Growth FactorMultipotent Stem CellsCell CycleNeurogenesisMouse Embryonic Stem CellsCell BiologyAnatomyCell DedifferentiationEmbryonic stem cellNeural stem cellCell biologyNeuroepithelial cell030104 developmental biologymedicine.anatomical_structureGene Expression RegulationAstrocytesMolecular MedicineFibroblast Growth Factor 2Stem cell030217 neurology & neurosurgerySignal TransductionDevelopmental BiologyAstrocyte
researchProduct

Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer.

2017

Summary Chronic inflammation drives the progression of colorectal cancer (CRC). Increased expression of interleukin (IL)-17A is associated with poor prognosis, and IL-17A blockade curbs tumor progression in preclinical models of CRC. Here we examined the impact of IL-1 signaling, a key regulator of the IL-17 pathway, in different cell types within the CRC microenvironment. Genetic deletion of the IL-1 receptor (IL-1R1) in epithelial cells alleviated tumorigenesis in the APC model of CRC, demonstrating a cell-autonomous role for IL-1 signaling in early tumor seed outgrowth. T cell specific ablation of IL-1R1 decreased tumor-elicited inflammation dependent on IL-17 and IL-22, thereby reducing…

0301 basic medicineCell typeColorectal cancerCarcinogenesisNeutrophilsmedicine.medical_treatmentImmunologyMedizinInflammationBiologymedicine.disease_causeArticle03 medical and health sciencesMice0302 clinical medicineSalmonellamedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansCells CulturedInflammationMice KnockoutTumor microenvironmentSalmonella Infections AnimalInterleukinsInterleukin-17InterleukinReceptors Interleukin-1medicine.disease030104 developmental biologyInfectious DiseasesCytokineTumor progressionOrgan Specificity030220 oncology & carcinogenesisCancer researchmedicine.symptomCarcinogenesisColorectal NeoplasmsInterleukin-1Signal TransductionImmunity
researchProduct

Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses

2016

Targeting antigen combined with adjuvants to hepatic antigen-presenting cells (APCs) is essential for the induction of intrahepatic T cellular immunity controlling and resolving viral infections of the liver. Intravenous injection of antigen-loaded nanoparticles is a promising approach for the delivery of antigens to liver APCs. Accordingly, polymeric nanocapsules (NCs) synthesized exclusively of hepatitis C virus non-structural protein 5A (NS5A) and the adjuvant monophosphoryl lipid A (MPLA) adsorbed to the nanocapsule surface were developed. Aim of the present study was the evaluation of the in vitro and in vivo behavior of MPLA-functionalized NS5A-NCs regarding the interaction with liver…

0301 basic medicineCellular immunityPolymersmedicine.medical_treatmentBiophysicsMonophosphoryl Lipid ABioengineeringViral Nonstructural ProteinsNanocapsulesBiomaterialsMice03 medical and health sciences0302 clinical medicineImmune systemNanocapsulesAntigenmedicineAnimalsParticle SizeCD40biologyHistocompatibility Antigens Class IIbiochemical phenomena metabolism and nutritionHepatitis CImmunity InnateMice Inbred C57BLLipid A030104 developmental biologyLiverMechanics of MaterialsImmunologyCeramics and Compositesbiology.proteinCytokinesFemaleImmunization030211 gastroenterology & hepatologyAntibodyAdjuvantBiomaterials
researchProduct

Cell-Autonomous and Non-cell-autonomous Function of Hox Genes Specify Segmental Neuroblast Identity in the Gnathal Region of the Embryonic CNS in Dro…

2016

During central nervous system (CNS) development neural stem cells (Neuroblasts, NBs) have to acquire an identity appropriate to their location. In thoracic and abdominal segments of Drosophila, the expression pattern of Bithorax-Complex Hox genes is known to specify the segmental identity of NBs prior to their delamination from the neuroectoderm. Compared to the thoracic, ground state segmental units in the head region are derived to different degrees, and the precise mechanism of segmental specification of NBs in this region is still unclear. We identified and characterized a set of serially homologous NB-lineages in the gnathal segments and used one of them (NB6-4 lineage) as a model to i…

0301 basic medicineCentral Nervous SystemCancer ResearchEmbryologyGene ExpressionNervous SystemNeural Stem CellsAnimal CellsMedicine and Health SciencesDrosophila ProteinsHox geneGenetics (clinical)Regulation of gene expressionGeneticsNeuronsMembrane GlycoproteinsDrosophila MelanogasterGene Expression Regulation DevelopmentalAnimal ModelsProtein-Tyrosine KinasesNeural stem cellCell biologyInsectsPhenotypesembryonic structuresDrosophilaDrosophila melanogasterAnatomyCellular Structures and OrganellesCellular TypesResearch Articleanimal structuresArthropodalcsh:QH426-470ImmunoglobulinsBiologyAntennapediaResearch and Analysis Methods03 medical and health sciencesModel OrganismsNeuroblastNuclear BodiesCyclin EGeneticsAnimalsGene RegulationCell LineageMolecular BiologyEcology Evolution Behavior and SystematicsLoss functionCell NucleusHomeodomain ProteinsNeuroectodermEmbryosOrganismsBiology and Life SciencesCell Biologybiology.organism_classificationInvertebrateslcsh:Genetics030104 developmental biologyCellular NeuroscienceDevelopmental BiologyNeurosciencePLoS Genetics
researchProduct

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

2018

Abstract Background: PIK3CA, a gene that encodes the α-isoform of the catalytic subunit of Class I PI3K (PI3Kα), is frequently mutated or amplified in solid tumors. Taselisib is an oral, potent, selective inhibitor of Class I PI3Kα, γ, and δ isoforms with enhanced activity against PIK3CA-mutated cancer models. Preclinical and clinical data demonstrated that single-agent taselisib has activity in multiple PIK3CA-mutated tumor types. Methods: This open-label phase I study (Cohort X of PMT4979g; NCT01296555) enrolled patients (pts) with PIK3CA-mutated tumors who had progressed after, or failed to respond to, at least one prior treatment regimen and were not candidates for regimens known to pro…

0301 basic medicineCervical cancerCancer Researchmedicine.medical_specialtybusiness.industryEndometrial cancerNot Otherwise SpecifiedCancermedicine.diseaseGastroenterologyHead and neck squamous-cell carcinoma03 medical and health sciencesRegimen030104 developmental biologyOncologyTolerabilityResponse Evaluation Criteria in Solid TumorsInternal medicinemedicinebusinessCancer Research
researchProduct

Chemical Composition, In Vitro Antitumor and Pro-Oxidant Activities of Glandora rosmarinifolia (Boraginaceae) Essential Oil

2018

The biological properties of essential oils have been demonstrated in the treatment of several diseases and to enhance the bioavailability of other drugs. In natural habitats the essential oils compounds may play important roles in the protection of the plants as antibacterials, antivirals, antifungals, insecticides and also against herbivores by reducing their appetite for such plants or by repelling undesirable others. We analyzed by gas-chromatography mass spectrometry the chemical composition of the essential oil of aerial parts of Glandora rosmarinifolia (Ten.) D.C. Thomas obtained by hydrodistillation and verified some biological activities on a panel of hepatocellular carcinoma cell …

0301 basic medicineChemical RadicalsAntioxidantmedicine.medical_treatmentMDA-MB-231Cancer Treatmentlcsh:MedicinenaphthoquinoneChemical CompositionBiochemistryPhysical ChemistryditerpeneAntioxidantslaw.invention0302 clinical medicinelawBreast TumorsSUM 149Medicine and Health SciencesBioassaySettore BIO/15 - Biologia FarmaceuticaCytotoxicitylcsh:ScienceMultidisciplinarybiologyTraditional medicineChemistryLiver DiseasesBoraginaceaeBoraginaceaeOxidantsHep3BLipidsChemistryOncology030220 oncology & carcinogenesisPhysical SciencesResearch ArticleHepG2Free RadicalsCell SurvivalGastroenterology and HepatologyCarcinomas03 medical and health sciencesInhibitory Concentration 50Cell Line TumorAromatic HydrocarbonsGastrointestinal TumorsBreast CancermedicineOils VolatileHumansPlant OilsEssential oilcytotoxic activityHA22T/VGH; HepG2; Hep3B; SUM 149; MDA-MB-231; cytotoxic activity; diterpenes; naphthoquinones; plant secondary metabolitesVolatile Organic CompoundsDose-Response Relationship DrugCell growthPlant ExtractsHA22T/VGHlcsh:RChemical CompoundsBiology and Life SciencesCancers and NeoplasmsEpithelial CellsHepatocellular CarcinomaSettore CHIM/06 - Chimica OrganicaPlant Components Aerialbiology.organism_classificationPro-oxidantplant secondary metabolitesAntineoplastic Agents PhytogenicHydrocarbonsBioavailability030104 developmental biologySettore BIO/03 - Botanica Ambientale E ApplicataHepatocytesSettore BIO/14 - Farmacologialcsh:QOils
researchProduct

2020

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also l…

0301 basic medicineChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerGeneral Medicinemedicine.disease3. Good healthRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinePermissivebusinessCells
researchProduct

Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit

2020

Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with an established benefit for patients suffering from primary biliary cholangitis (PBC). It was first introduced in the 60s and took until the late 90s to demonstrate a survival benefit in large meta-cohort studies.1 Since then, UDCA is the established first-line therapy according to current guidelines.2 The benefit of UDCA is multidimensional, and patients receiving UDCA experience increased transplant-free survival, a decreased risk of hepatocellular carcinoma and potentially improved quality of life.3–5 The survival benefit is predicted by a number biochemical markers that reflect cholestasis and that are accepted surrogates of the…

0301 basic medicineCholagogues and Cholereticsmedicine.medical_specialty2312Cholangitismedicine.drug_classBiliary cirrhosisclinical decision makingliverGastroenterologyhepatobiliary disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePrimary biliary cirrhosisCholestasisInternal medicinemedicineHumans1506BezafibrateHepatologyBile acidLiver Cirrhosis Biliarybusiness.industryUrsodeoxycholic AcidGastroenterologyObeticholic acidmedicine.diseaseUrsodeoxycholic acidLiver Transplantationprimary biliary cirrhosis030104 developmental biologychemistryHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugGut
researchProduct